← boardnext 2026-12next 2027-12
OCS
Oculisdistress 0/10 · well-funded / low risk$11.23-2%today-66% from 52w high
Metabolic / Obesity 2
Lead: Diabetic Macular Edema
Revenue
pre-revenue
Liquidity
$222M
Runway
3.4 yrs
Shares 1y
—
Price & events
-58.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-10.9%
1W
-4.2%
1M
-58.1%
3M
-58.6%
6M
-37.9%
1Y
-2.6%
2Y
+16.4%
5Y
+15.8%
All
Overview
- Volume
- 19.01K
- 52 Week Range
- $10.71 – $32.65
- Float Shares
- 52.12M
- Short %
- 2.26%
- % Held by Insiders
- 3.51%
- % Held by Institutions
- 38.98%
- RVOL
- 0.04x
- Beta
- 0.20
Pipeline stages · 3 programs
licaminlimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Privosegtor, Methylprednisolone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dexamethasone ophthalmic suspension (OCS-01), Vehicle
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 2/3 | licaminlimab | Dry Eye Disease (DED) | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-02-14 | Phase 3 | Privosegtor, Methylprednisolone | Optic Neuritis | — | recruiting |
| 2026-04-10 | Phase 2/3 | Dexamethasone ophthalmic suspension (OCS-01), Vehicle | Diabetic Macular Edema | 552 | completed |
| 2026-04-02 | Phase 3 | Dexamethasone ophthalmic suspension (OCS-01), Vehicle | Diabetic Macular Edema | 401 | completed |
Catalyst news & presentations · 1
- 2026-08-06Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $37 (+232% upside) · 11 analysts
- 2026-06-03JP MorganOverweight
- 2026-06-02BairdOutperform
- 2026-06-01StifelBuy
- 2026-06-01NeedhamBuy
- 2026-06-01GuggenheimBuy
- 2026-06-01HC Wainwright & Co.Buy
Competitors — Diabetic Macular Edema
- ABBVAbbVie Inc.$451.1B · D2
- BCRXBIOCRYST PHARMACEUTICALS INC$2.4B · D1
- EYPTEyePoint, Inc.$1.0B · D6
- ALVOAlvotech$1.0B · D3
- BIOABioAge Labs, Inc.$956M · D1
- FDMT4D Molecular Therapeutics, Inc.$524M · D5
- OCGNOcugen, Inc.$423M · D7
- OTLKOutlook Therapeutics, Inc.$157M · D10
- CLSDQClearside Biomedical, Inc.$1M · D4
Recent news
- 2026-07-23Technical Reactions to OCS Trends in Macro Strategies - Stock Traders Daily
- 2026-07-22Guggenheim initiates coverage of Oculis Holding (OCS) with buy recommendation - MSN
- 2026-07-20Oculis Holding AG (OCS) Investigation: Bronstein, Gewirtz & Gross - The National Law Review
- 2026-07-20Number of shareholders of Oculis Holding AG – NASDAQ:OCSAW - TradingView
- 2026-07-15Bronstein, Gewirtz & Grossman, LLC Is Investigating Oculis Holding AG (OCS) And Encourages Investors to Connect - The National Law Review
- 2026-07-08Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Yahoo Finance
- 2026-07-02Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewswire
- 2026-07-02Oculis spotlights late-stage eye drugs at Piper Sandler event - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.